Physician profile
John B Gill
NPI 1487737177
$2,034.05
in general payments reported to CMS, 2019-2025
26 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $247 · 2021: $237 · 2022: $110 · 2023: $178 · 2024: $52.03 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $365.44 | 2019-2022 | |
| Medtronic Vascular, INC. | $264.08 | 2019-2020 | |
| Amgen INC. | $214.67 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $176.85 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $154.37 | 2019-2021 | |
| Penumbra, INC. | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $91.22 | 2019-2025 | Lokelma |
| Merck Sharp & Dohme LLC | $76.84 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $71.18 | 2019-2020 | |
| Cardiovascular Systems INC. | $62.49 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $51.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $43.37 | 2019 | |
| Welch Allyn | $42.38 | 2019 | |
| Shockwave Medical, INC | $40.61 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.25 | 2022 | |
| Pfizer INC. | $25.05 | 2025 | |
| Abbott Laboratories | $20.81 | 2019 | |
| Ethicon US, LLC | $19.58 | 2021 | |
| Abiomed | $15.07 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.36 | 2023 | Inpefa |
| Amarin Pharma, INC. | $12.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 | |
| Esperion Therapeutics, INC. | $11.61 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.